2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: University of California San Francisco

Poster-Neurophysiology; Neuropsychology and Neuropsychiatry

October 25, 2021

Stability of the Gut Microbiota in Persons with Pediatric-Onset Multiple Sclerosis and Related Demyelinating Diseases

Background: Little is known about the stability of the gut microbiota in multiple sclerosis (MS) over time. Objectives: To determine if the...

Read More →

Poster-Imaging

October 25, 2021

Neural Correlates of Hand Motor Function Revealed By Structural MR Imaging: A Smartphone-Based Remote Assessment Study in People with MS

Background: Regional gray matter pathology is associated with hand motor impairment in people with multiple sclerosis (PwMS). Objectives:...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis

Background: Ozanimod is approved in the US for the treatment of adults with relapsing multiple sclerosis (RMS) and in the EU and Canada for...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study

Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years

Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Expand Study

Background: Siponimod is a selective S1P receptor (S1P1 and S1P5) modulator, approved in the USA for treatment of relapsing forms of MS,...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS

Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Immunoglobulin Kinetics and Infection Risk after Long-Term Inebilizumab Treatment for Neuromyelitis Optica Spectrum Disorder

Background: Long-term use of B-cell depleting monoclonal antibodies is associated with reduced immunoglobulin (Ig) levels that can...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years

Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...

Read More →

Platform-Disease Modifying Therapies

October 25, 2021

Efficacy and Safety of Ublituximab Versus Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase 3 Ultimate I and II Trials

Background: Ublituximab, a novel monoclonal antibody, targets a unique epitope on the CD20 antigen and is glycoengineered for enhanced...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC